ArticleAnnals of neurology2018
Serotonin, β-amyloid, and cognition in Parkinson disease.
Article in Annals of neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 60 citations in OpenAlex.
- Apathy linked to higher amyloid burden and cognitive deterioration in Parkinson's disease.Journal of Parkinson's disease · 2025Observational
- Neuroprotective Attributes of Gut-derived Urolithins in Parkinson's Disease.Molecular neurobiology · 2025Review
- Disease-specific neuropathological alterations of the locus coeruleus in Alzheimer's disease, Down syndrome, and Parkinson's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Fatigue and neuropsychiatric symptoms in Parkinson's disease: a narrative review.Frontiers in neurology · 2025Review
- Exploring Analysis Approaches for Using the Dopamine Transporter Striatal Binding Ratio in Early- to Mid-Stage Parkinson's Disease Modification Trials.Movement disorders clinical practice · 2024Article
- Correlations between serotonin impairments and clinical indices in multiple system atrophy.European journal of neurology · 2024Article
- Serotonergic neurotransmission mediated cognitive dysfunction in two mouse models of sepsis-associated encephalopathy.CNS neuroscience & therapeutics · 2024Article
- Serotonin transporter density in isolated rapid eye movement sleep behavioral disorder.Frontiers in sleep · 2024Article
- How should we be using biomarkers in trials of disease modification in Parkinson's disease?Brain : a journal of neurology · 2023Article
- Targeting the blood-brain barrier to delay aging-accompanied neurological diseases by modulating gut microbiota, circadian rhythms, and their interplays.Acta pharmaceutica Sinica. B · 2023Review
- Machine learning-based prediction of longitudinal cognitive decline in early Parkinson's disease using multimodal features.Scientific reports · 2023Article
- The Serotonergic System and Amyotrophic Lateral Sclerosis: A Review of Current Evidence.Cellular and molecular neurobiology · 2023Review
- Regional serotonin terminal density in aging human brain: A [Aging brain · 2023Article
- Multidirectional associations between the gut microbiota and Parkinson's disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway.Frontiers in cellular and infection microbiology · 2023Review
- Outcome Measures for Disease-Modifying Trials in Parkinson's Disease: Consensus Paper by the EJS ACT-PD Multi-Arm Multi-Stage Trial Initiative.Journal of Parkinson's disease · 2023Article
- Serotonin Transporter Imaging in Multiple System Atrophy and Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2022Article
- Migraine Pharmacological Treatment and Cognitive Impairment: Risks and Benefits.International journal of molecular sciences · 2022Review
- Retinal Nerve Fiber Layer Thickness and Associations With Cognitive Impairment in Parkinson's Disease.Frontiers in aging neuroscience · 2022Article
- Emerging Neuroimaging Biomarkers Across Disease Stage in Parkinson Disease: A Review.JAMA neurology · 2021Review
- Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares.Translational psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectiveSerotoninergic neurotransmission may modulate β-amyloid peptide (Aβ) metabolism through upregulation of α-secretase. Early Parkinson disease (PD) shows variable serotoninergic denervation, which may impact Aβ deposition.
methodsWe conducted 3 analyses to explore associations between serotoninergic neurotransmission and cerebral Aβ burden in PD. The first was a cross-sectional imaging study of PD subjects (n = 23) using the serotoninergic transporter positron emission tomography (PET) ligand [
resultsSerotoninergic DASB distribution volume ratio (DVR) inversely associated with PiB DVR in the cerebral cortex (Pearson r = -0.478, p = 0.021) but not the striatum (r = -0.264, p = 0.224). In the baseline PPMI analysis, serotoninergic medication use for ≥6 months associated with a lower level of CSF Aβ-42 (t = -2.20, p = 0.029). In the longitudinal PPMI model, baseline serotoninergic medication use associated with a reduced risk of cognitive decline (t = -2.03, p = 0.043) after controlling for covariates.
interpretationCortical Aβ burden in PD associates inversely with serotoninergic innervation. Serotoninergic medications may alter Aβ metabolism and reduce the risk of PD cognitive decline. Ann Neurol 2018;83:994-1002.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.